SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2015, and provided an operating forecast and program updates.
Financial highlights for the 2015 fourth quarter include:
• Fourth quarter total revenues were $21.2 million and royalty revenues were $11.5 million.
• Fourth quarter adjusted EPS was $0.66 and GAAP EPS was $0.29.
